早期应用替罗非班对急性STMI急诊介入治疗慢血流的影响及安全性

目的 探讨早期应用替罗非班对急性ST段抬高心肌梗死（STMI）经皮冠状动脉介入治疗（PCI）中慢血流的影响及安全性.方法 将90例急性STMI患者随机分为替罗非班组（45例）和对照组（45例）.比较两组患者梗死相关血管PCI后即刻TIMI血流、校正TIMI帧数计数（cTFC）、90 min ST段回落百分比、出血和血小板减少的发生率.结果与对照组相比,替罗非班组PCI后慢复流发生率降低（P〈0.05）,90 min内ST段回落百分比提高;两组患者均未出现住院期间死亡及急性血栓形成,出血情况差异无统计学意义（P〉0.05）.结论 早期应用替罗非班能改善急性STMI患者PCI后梗死相关血管的慢血流的发生,临床应用安全有效.

Efficacy on slow bleeding and safety of early using of tirofiban in patients with acute STMI accepted PCI

Objective To study the curative effect of early initiation of tirofiban on patients undergoing emergency percutaneous coronary intervention （PCI） and its safety. Methods Ninety patients with ST - segment elevated myocardial infarction （STEMI） undergoing emergency PCI were randomized to two groups ：tirofiban group （ n = 45,with early administration of tirofiban immediately in emergency department） and control group （n = 45）. TIMI flow, corrected TIMI frame count （ cTFC , and ST segment resolution 90 rain after PCI of two groups were compared. The incidences of bleeding complications and thrombocytopema were registered to assess the safety. Results The cTFC and blood flow velocity in tirofiban group were significantly improved compared with those in control （ P 〈 0.05 ） ; the proportion of ST segment resolution was significantly higher in tirobiban group than that in control group. However, no significant difference was observed in major adverse cardiac events and bleeding between the two groups. Conclusion Early administration of tirofiban before emergency PCI improves myocardial reperfusion and reduces occurrence of slow - flow in patients undergoing primary PCI.